OCD drug developer Exscientia bagged $60m in a Novo-led round that also featured Bristol-Myers Squibb and existing corporate investor Evotec.
Novo led a $60m series C round today for Exscientia, a UK-based drug discovery technology spinout of University of Dundee, that included fellow pharmaceutical firm Bristol-Myers Squibb.
The round also featured Evotec, a company that pursues drug discovery and development partnerships, as well as private equity firm GT Healthcare Capital, which took part through unnamed limited partners.
Exscientia has built an artificial intelligence-equipped drug discovery platform that taps into the outcomes of historic research to design compounds and rapidly progress…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
